<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151295">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01834989</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2012-078</org_study_id>
    <nct_id>NCT01834989</nct_id>
  </id_info>
  <brief_title>Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I</brief_title>
  <acronym>IGF-I</acronym>
  <official_title>Effect of Training and Local Infusion of Insulin-like Growth Factor-I and Training on Tendon Structure in Patients With Patellar Tendinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the hypothesis that stimulation of the synthesis of new
      structural tendon proteins combined with training improve the tendon structure in patients
      with chronic knee tendon pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled intervention study: 12 weeks intervention period with training and
      injections of saline or Insulin-Like growth factor I. One year follow-up
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Tendon structure</measure>
    <time_frame>After 12 weeks intervention (tendon biopsy)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tendon Pain</measure>
    <time_frame>1 year (before and after 12 weeks intervention and 1 year after intervention start)</time_frame>
    <safety_issue>No</safety_issue>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>Insulin-like growth factor I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin-like growth factor I</intervention_name>
    <arm_group_label>Insulin-like growth factor I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic patellar tendinopathy (&gt; 3 months)

          -  anterior-posterior thickening of the tendon (1 mm compared to mid-tendon)

          -  hypo-echoic area with enhanced vascularization

        Exclusion Criteria: injection

          -  corticosteroid injection within the last 12 months

          -  Knee operation

          -  Knee osteoarthritis

          -  Diabetes

          -  Smoking

          -  Body mass index &gt;30
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kjaer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Sports Medicine, Copenhagen, Bispebjerg Hospital, 2400 Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mette Hansen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of Sport Science, Department of Public Health, Aarhus University, Dalgas Avenue 4, 8000 Aarhus C, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Olesen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Sports Medicine, Copenhagen, Bispebjerg Hospital, 2400 Copenahagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette Hansen, Ass. Professor</last_name>
    <phone>+45 51666551</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Kjaer, Professor</last_name>
    <phone>+45 35316089</phone>
    <email>m.kjaer@mfi.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Sports Medicine, Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kjaer, Professor</last_name>
      <phone>+4535316089</phone>
      <email>m.kjaer@mfi.ku.dk</email>
    </contact>
    <contact_backup>
      <last_name>Mette Hansen, Ass. Profes.</last_name>
      <phone>+45 51666551</phone>
      <email>kontakt@mettehansen.nu</email>
    </contact_backup>
    <investigator>
      <last_name>Mette Hansen, Ass. Profes.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Kjaer, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Olesen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.ismc.dk</url>
    <description>Study location</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 16, 2013</lastchanged_date>
  <firstreceived_date>April 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Mette Hansen</investigator_full_name>
    <investigator_title>Associated Professor, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Complement Factor I</mesh_term>
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
